MicroRNA ‐218 was stably overexpressed in four cervical cancer cell lines and a series of in vitro and in vivo experiments were performed to investigate cellular sensitivity to Rapamycin. In primary cultured cervical cancer cells, the expression of microRNA ‐218 was negatively correlated with the mRNA level of Rictor, which predicted cellular sensitivity to Rapamycin (p = 0.002, R2 = 0.6810). In vitro , overexpression of microRNA ‐218 significantly reduced the level of Rictor and enhanced the growth‐inhibition, cell cycle arrest, and apoptosis induced by Rapamycin. In vivo , overexpression of microRNA ‐218 further enhanced the suppressive effects of Rapamycin on tumor growth.